ANIK Q3 2024 Earnings — Anika Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ANIKAnika Therapeutics, Inc.

$213M

Q3 2024 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$39M-6.5% YoY

Gross Profit

$1M3.7% margin

Operating Income

-$28M-72.3% margin

Net Income

-$30M-77.2% margin

EPS (Diluted)

$-2.03

QoQ Revenue Growth

+26.1%

Cash Flow

Operating Cash Flow

$5M

Free Cash Flow

$3M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$231M

Total Liabilities

$52M

Stockholders' Equity

$180M

Cash & Equivalents

$62M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$39M	$41M	-6.5%
Gross Profit	$1M	$25M	-94.2%
Operating Income	-$28M	-$8M	-265.1%
Net Income	-$30M	-$7M	-355.0%

Revenue Segments

Joint Preservation and Restoration

$12M83%

Non-Orthopedic

$2M17%

Geographic Segments

UNITED STATES

$28M83%

Europe

$6M17%